Janssen Pharma: Phase 3 Study of Ponesimod Met Primary, Most Secondary Endpoints

Date : 07/25/2019 @ 9:20PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 141.38  0.04 (0.03%) @ 12:59AM
After Hours
Last Trade
Last $ 141.38 ◊ 0.00 (0.00%)

Janssen Pharma: Phase 3 Study of Ponesimod Met Primary, Most Secondary Endpoints

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

6 Months : From Jun 2019 to Dec 2019

Click Here for more Johnson and Johnson Charts.
   By Stephen Nakrosis 

The Janssen Pharmaceutical Companies of Johnson & Johnson said Thursday that results from its Phase 3 Optimum study met primary and most secondary endpoints.

The Optimum study evaluated the efficacy and safety of ponesimod compared to Aubagio, or teriflunomide, in adult patients with relapsing multiple sclerosis, the company said. The primary endpoint of the Optimum study was annualized relapse rate up to the end of the study, the company said.

Janssen said, "The safety profile observed for ponesimod in the Optimum study was consistent with previous studies of ponesimod."

The company said, "Data from the Optimum study will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of ponesimod as a treatment for relapsing forms of multiple sclerosis, which are anticipated for later this year."


--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

July 25, 2019 17:05 ET (21:05 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.